SCHEMBL2322728

SCHEMBL2322728

NS(=O)(=O)CC(O)c1cc(Cl)ccc1Cl

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.38
TSHR P16473 3/20 0.38
HSD17B10 Q99714 2/20 0.38
CYP3A4 P08684 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
GABBR2 O75899 1/20 0.38
GABBR1 Q9UBS5 1/20 0.38
CA1 P00915 2/20 0.36
CA2 P00918 2/20 0.36
POLB P06746 2/20 0.35
LMNA P02545 1/20 0.35
CA12 O43570 1/20 0.35
CA9 Q16790 1/20 0.35
TP53 P04637 2/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
KDM4E B2RXH2 1/20 0.34
MAPT P10636 1/20 0.34
MCL1 Q07820 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2322723 0.80 CA2 (0.39) ALDH1A1TSHRHSD17B10CYP3A4TDP1
SCHEMBL2328728 0.79 AOC3 (0.51) TSHRCYP3A4TDP1LMNAKDM4E
SCHEMBL2319714 0.79 AOC3 (0.51) TSHRCYP3A4TDP1LMNAKDM4E
SCHEMBL2323243 0.79 AOC3 (0.51) TSHRCYP3A4TDP1LMNAKDM4E
SCHEMBL20189690 0.78 APLNR (0.41) CYP3A4GABBR2GABBR1
SCHEMBL20188401 0.78 APLNR (0.41) CYP3A4GABBR2GABBR1
SCHEMBL20188403 0.78 APLNR (0.41) CYP3A4GABBR2GABBR1
SCHEMBL12438379 0.78 TP53 (0.41) ALDH1A1TSHRHSD17B10CYP3A4TDP1
SCHEMBL7152846 0.78 TP53 (0.41) ALDH1A1TSHRHSD17B10CYP3A4TDP1
Hydrochloric Acid SCHEMBL2323324 0.77 TDP1 (0.40) ALDH1A1TSHRHSD17B10CYP3A4TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120302546-A1 NOVEL SULFAMIDES EXHIBITING NEUROPROTECTIVE ACTION AND METHODS FOR USE THEREOF FOX CHASE CHEMICAL DIVERSITY CENTER, INC. (US) 2012-11-29 US claimed
WO-2011097337-A1 NOVEL SULFAMIDES EXHIBITING NEUROPROTECTIVE ACTION AND METHODS FOR USE THEREOF ADVANCED NEURAL DYNAMICS, INC. (US) 2011-08-11 WO claimed
US-20120302546-A1 NOVEL SULFAMIDES EXHIBITING NEUROPROTECTIVE ACTION AND METHODS FOR USE THEREOF FOX CHASE CHEMICAL DIVERSITY CENTER, INC. (US) 2012-11-29 US disclosed
WO-2011097337-A1 NOVEL SULFAMIDES EXHIBITING NEUROPROTECTIVE ACTION AND METHODS FOR USE THEREOF ADVANCED NEURAL DYNAMICS, INC. (US) 2011-08-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120302546-A1 NOVEL SULFAMIDES EXHIBITING NEUROPROTECTIVE ACTION AND METHODS FOR USE THEREOF GRIK2, GRIK5, GRIN2A ALDH1A1 648/4885TSHR 4311/4885HSD17B10 1095/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.